Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Nektar Therapeutics (NKTR)

Nektar Therapeutics (NKTR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Nektar: Q3 Earnings Snapshot AP - Thu Nov 7, 3:36PM CST

Nektar: Q3 Earnings Snapshot

NKTR : 1.3700 (-1.44%)
Healthcare - Medicine labratory by gorodenkoff via iStock
Wall Street is Overlooking This Penny Stock, Says Analyst Barchart - Fri Oct 4, 12:25PM CDT

This penny stock could surge up to 200%, according to one bull, who has high hopes for a pipeline drug ahead of trial data due out in 2025.

AAPL : 227.48 (+2.14%)
AMZN : 210.05 (+1.43%)
NKTR : 1.3700 (-1.44%)
Nektar: Q2 Earnings Snapshot AP - Thu Aug 8, 3:49PM CDT

Nektar: Q2 Earnings Snapshot

NKTR : 1.3700 (-1.44%)
Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress PR Newswire - Fri Oct 13, 2023

/PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced new data for rezpegaldesleukin (REZPEG), a first-in-class selective regulatory T-cell (Treg)...

NKTR : 1.3700 (-1.44%)
Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy PR Newswire - Mon Oct 2, 2023

/PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will have two presentations for rezpegaldesleukin (REZPEG), a first-in-class...

NKTR : 1.3700 (-1.44%)
Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer PR Newswire - Wed Sep 27, 2023

/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it has entered into a new clinical study collaboration with Cellular Biomedicine Group...

NKTR : 1.3700 (-1.44%)
Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th PR Newswire - Wed Sep 6, 2023

/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host a virtual investor and analyst event on Wednesday, September 13, 2023 at...

NKTR : 1.3700 (-1.44%)
Nektar Therapeutics Reports Second Quarter 2023 Financial Results PR Newswire - Tue Aug 8, 2023

/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2023. Cash and investments in...

NKTR : 1.3700 (-1.44%)
Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company PR Newswire - Mon Aug 7, 2023

/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that efficacy data previously generated by Eli Lilly & Company for rezpegaldesleukin...

NKTR : 1.3700 (-1.44%)
Nektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial Markets PR Newswire - Tue Aug 1, 2023

/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2023 on Tuesday, August 8, 2023, after the close...

NKTR : 1.3700 (-1.44%)

Barchart Exclusives

1 Energy Dividend Stock That Just Hiked Its Cash Flow Forecast Barchart - Thu Nov 7, 6:30PM CST
Analysts are optimistic about this dividend-paying energy company, which raised its cash flow forecast after surging LNG demand pushed it past Q3 expectations. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot